RA Flashcards

1
Q

What is RA?

A

Chronic, systemic inflammatory condition Causes progressive destruction of bone /cartilage around joint

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which part of the body is affected first by RA?

A

Interphalangeal joints of fingers and wrist are usually affected first.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which part of the body is later affected by RA?

A

Ankles and hips may be affected later

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What kind of symptoms are associated with RA?

A
  • Affected joints warm, swollen and painful

- Increased extracellular fluid around joint causes stiffness particularly in the morning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Increased risk of co-morbidity associated with RA

A
  • Cardiovascular disease
  • Inflammation around lungs and heart
  • Systemic symptoms e.g. malaise / weight loss
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What type of arthritis is RA?

A

Deforming arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is septic arthritis?

A
  • Secondary to infection

- Invasion of joints by an infectious agent resulting in joint inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is Post traumatic arthritis?

A

Secondary to physical injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Two main T-helper cells involved in autoimmunity?

A

TH-1 and TH-17

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is RA triggered by?

A

Exposure of a genetically susceptible individual to an arthritogenic antigen resulting in a breakdown of immunological self-tolerance and a chronic inflammatory reaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the genetic competent of RA?

A

Mutations in Major Histocompatibility Complex Class II are a strong predictor of
risk (HLA-DR4 allotype increased among RA patients)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is normal in terms of tolerance in the body?

A

There is a balance between protection and tolerance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What does initiating event do to the tolerance of self-antigens?

A

Breakdown of tolerance – acute arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What may be the cause of most initiating events? (2)

A

Infection or injury (along with genetic competent)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is important for the initiating event to occur?

A

Genetic component (not everyone with injury or infection will cause breakdown of tolerance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What happens after the initiating event in terms of T-helper cells?

A

CD4+ T helper cells get activated causing autoimmune reaction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What happens as the autoimmune reaction progresses?

A

Release of inflammatory cytokines and mediators leading to joint destruction and inflammation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What does release of inflammatory cytokines and mediators cause?

A

Joint destruction and inflammation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

3 main steps in RA?

A
  1. Intiating event
  2. CD4+ T helper cells activated
  3. Releae of inflammatory cytokines and mediators
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the main CD4+ T helper cells that infiltrate the joints?

A

Th17

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What does Th17 activate?

A

Macrophages to secrete pro-inflammatory cytokines (IL-1 and TNF-alpha) and help B cells to produce further arthritogenic antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What pro-inflammatory cytokines are secreted from macrophages (after Th17 ha activated it)?

A

IL-1 and TNF-alpha

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What do cytokines (IL-1 and TNF-alpha) activate?

A

Synovial fibroblasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What do Synovial fibroblasts release in response to the cytokines? (2)

A

Secrete matrix metalloproteases (MMP) – damage tissue

Secrete RANKL which activates osteoclasts -breakdown bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What does secretion of matrix metalloproteases (MMP) in synovial fibroblasts do?

A

Damage tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What does secretion of RANKL which activate osteoclasts in synovial fibroblasts do?

A

Breakdown bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What are Treg T-helper cells?

A

Maintain the balance between self and non-self cells. So can supress and abnormal immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

RA autoimmune reaction and joint destruction? (4)

A
  1. Unknown trigger causes inflammation in the synovial membrane attracting leukocytes into tissue
  2. CD4+ T helper cells activate macrophages to secrete proinflammatory cytokines
  3. Cytokines induce MMP and RANKL by synovial fibroblasts
  4. MMP attack tissue and, osteoclasts breakdown bone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Two autoantibodies found in RA?

A
Rheumatoid factor (RF)
 Anti-citrullinated peptide antibody (ACPA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is RF?

A

Rheumatoid factor which is and auto antibody that recognises the Fc portion of IgG antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What type of antibody can RF be? )3)

A

IgM, IgG and IgA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

RA autoimmune reaction and joints destructions (genetic component)

A

Mutations in Major histocompatibility complex class II are strong predictor of risk (HLA-DR4 allotype increased among RA patients.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Why is RF important in RA?

A

Cause formation of immunocomplexes that deposit within the joint?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Does RF indicate RA?

A

No, found 30% of SLE patients, but is found in most RA patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What is ACPA?

A

Anti-citrullinated peptide antibody, directed against peptides and proteins that are citrullinated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

When is citrullination increased?

A

With inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Does smoking correlate with citrullination?

A

Yes (high risk factor that increases production of citrullinated proteins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Why is smoking associated with citrullination? (7)

A
  1. Induces the expression of PAD in the respiratory tract.
  2. Citrullinated proteins are formed in the respiratory tract.
  3. Presentaion of citrullinated self-peptides by MHC II (HLA-DRA) can activate specific CD4 T cells.
  4. CD4 T cells help and activate B cells
  5. B cell produce antibodies to our own citrullinated proteins
  6. Stimuliates autoimmune response
  7. Pre-artivcular phase
39
Q

Which proteins in the extracellular matrix can be citrullinated? (3)

A

Fibrin, fibrinogen collagen and vimentin.

40
Q

Citrulline

A

Amino acid related to arginine that is NOT used in protein synthesis

41
Q

Citrullination

A

Mechanism that converts arginine into citrulline

42
Q

What enzymes is citrullination catalysed by?

A

Peptidylargine deiminases (PAD)

43
Q

What does PAD do to arginine (amino acid)?

A

Converts arginine (+) into citrulline (neutral), done by destabilizing proteins which makes them more prone to proteolysis.

44
Q

What does the conversion arginine (+) to citrulline (-) do?

A

Makes them more prone to proteolysis. (More easily degraded). Exposes more epitopes.

45
Q

What is proteolysis?

A

Protein is broken down partially, into peptides, or completely, into amino acids, by proteolytic enzymes. Exposes more epitopes.

46
Q

What does exposure of more epitopes from pyrolysis do?

A

Recognised by B and T cells causing and autoimmune reaction

47
Q

RA stages of pathogenesis

A
  1. Pre-articular phase
  2. Initiation phase
  3. Progression
48
Q

What is the pre-articular phase?

A

When autoantibodies are produced (ACPA and RF) and present in the blood but do not have access to the joint capsule. This can happen years before symptoms of RA.

49
Q

What do PAD2 and PAD4 do in the synovial fluid? (pre-articular phase)

A

PAD2 and PAD4 in the synovial fluid citrullinate unknow proteins in the joint capsule.

50
Q

What is RA initiation?

A
  1. RA initiated by joint damage (wound/infection)
  2. Damage induces a state of inflammation and lead to further activation of PAD.
  3. Symtoms occur
51
Q

What does increase in vascular permeability do in RA initiation?

A

Allows ACPA and RF to enter the joint capsule from the blood.

52
Q

What does the ACPA, RF and lymphocytes entering the joint capsule do?

A

They will bind to the citrullinated proteins (citrullinated protein-autoantibody complex) and exacerbate inflammation.

53
Q

What do lymphocytes (T cells) do in the Initiation phase?

A

Infiltrate the inflamed joint tissue and responds to their specific antigens.

54
Q

What happens in RA initiation?

A
  1. Joint damage (wound/infection)
  2. Infalmmation causes activation of PAD
  3. Incrased vascular permeability and ACPA and RF enter join capsule
  4. Lymphoctes infiltrate and respond to specific antigens.
  5. The action of T cell and deposition of immune complexes exacerbate the inflammation and lead to RA symptoms.
55
Q

What do the CD4 T helper cells differentiate to when they have infiltrated the cells?

A

TH17 and TH1

56
Q

What does TH17 release in RA progression?

A

IL-17 and recruiting neutrophils and monocytes, causing amplification of the inflammation.

57
Q

What does IL-17 activate in RA progression?

A

Synoviocytes which releases RANKL

58
Q

What does TH1 release in RA progression?

A

IFN-gamma and activating macrophages

59
Q

What other pro-inflammatory cytokines and mediators macrophages and synoviocites produce in RA progression?

A

IL-1, IL-6, TNF, NO, PGE2 ,RANKL

60
Q

What does the synovial membrane and fibrous layer?

A

Together form the joint capsule

61
Q

What is the joint capsule made up of?

A

Synovial membrane and fibrous layer

62
Q

What are PAD2 AND PAD4?

A

Enzymes found in the synovial fluid

63
Q

4 drug classes that can be used for RA

A

NSAIDs
Glucocorticoids
DMARDs
Biologics

64
Q

What do NSAIDs do for RA?

A

Pein relief and reduces inflammation but does not affect the progression.

65
Q

NSAID example

A

Aspirin daily

66
Q

What do glucocorticoids do for RA?

A

Reduces inflammation.
Reduce development of joint damage (damage to joint capsule in RA is permanent and so aim of therapy is to slow rate of damage as much as possible

67
Q

What do DMARDs do for RA?

A

First line treatment: Pain relief, reduces swelling/stiffness and slows disease progression. (not that good for ongoing inflammation)

68
Q

What do Biologics do for RA?

A

Targeted e.g. to inflammatory cytokines, reduces symports and slows proregression

69
Q

Glucocorticoid example

A

Prednisolone daily

70
Q

DMARDs example

A

Methotrexate weekly

71
Q

Biologics example

A

Anti-TNF weekly to monthly

72
Q

Methotrexate (DMARD) in RA (3)

A
  • Suppresses neutrophil adhesion to blood vessels and so prevents entry to site of inflammation
  • Suppresses cytokine production
  • Reduces macrophage function
73
Q

What does suppression of cytokine production and reduction of macrophage function do to immune function (methotrexate)?

A

Reduce immune function, which mean the patient is more susceptible to other infections.

74
Q

Methotrexate side effect/cons

A

Immunological suppression means that patients more susceptible to other infections

75
Q

Sulfasalazine (DMARD) in RA (4)

A
  • Unclear mode of action
  • Metabolised in the gut to sulfapyridine
  • Both compounds can be found in synovial fluid -Sulfasalazine can suppress signalling pathways involved in synthesis of pro-inflammatory cytokines
76
Q

Sulfasalazine side effect/cons

A

High doses – needed to be effective,

  • GI disturbances common
  • Induces reversible oligospermia
  • Blood dyscrasias – changes to numbers of white cells
77
Q

Leflunomide (DMARD) in RA (5)

A
  • Inhibits an enzyme involved in synthesis of uridine monophosphate (UMP)
  • Inhibits tyrosine kinases
  • These effects supress expansion of autoimmune lymphocytes
  • Suppresses autoimmunity
  • Lefunomide is a prodrug –converted to active form in intestinal mucosa and plasma
78
Q

Leflunomide side effect/cons

A
  • Many side effects including hepatotoxicity and teratogenicity
  • Also leukopenia, anaemia and thrombocytopenia
  • Monitoring of blood count / liver function therefore needed
79
Q

Leflunomide monitoring

A

Monitoring of blood count / liver function therefore needed

80
Q

Hydroxychloroquine in RA (5)

A
  • Antimalarial drug
  • Appears to enter lysosomes inside cell and disturb pH
  • Macrophages depend upon acid protease for digestion of intracellular protein
  • Altered pH inside lysosome may alter processing of peptide antigens
  • Reduces activity of other immune cells
81
Q

Hydroxychloroquine side effect/cons

A
  • Major unwanted effect – retinal toxicity

- Mainly used as an alternative to previous drugs in patients with mild RA

82
Q

Cons of biologics

A

Tend to be expensive so inly used when DMARDs do not work.

83
Q

Anti-TNF (biological therapy)

A
  • First biologics developed
  • antibodies against tumour necrosis factor α(TNF), an important mediator of inflammatory responses
  • or more complex fusion proteins that act in the same way
84
Q

Anakinra (biological therapy)

A

Antibody against IL-1 receptor. IL-1 is a pro-

inflammatory cytokine released from activated macrophages

85
Q

Tocilzumab (biological therapy)

A

Antibody that acts as competitive antagonist
against the IL-6 receptor
- Thereby preventing IL-6 binding and subsequent downstream signalling

86
Q

Biological therapies

A
  • Biologics target specific components of the immune signalling pathway that are important in the inflammation associated with RA
  • Used when conventional DMARDS are ineffective
87
Q

RA pathogenesis summary (5)

A
  1. Break in tolerance to self-citrullinated proteins in the body and production of autoantibodies
  2. An injury to the joint
  3. CD4+ T cells activation
  4. Release of cytokines, RANKL and other enzymes
  5. Osteoclast activation and bone destruction
88
Q

Infliximab

A

Chimeric mAb

89
Q

Adalimumab

A

Human mAb

90
Q

Certolizumab pegol

A

Humanized mAb

91
Q

Etanercept

A

TNFR fusion protein

92
Q

Golimumab

A

Human mAb

93
Q

5 different antibodies for biological therapy in RA

A
Infliximab 
 Adalimumab 
 Certolizumab pegol 
 Etanercept 
 Golimumab